$0.504
-0.015 (-2.97%)Zum Schluss
RKDA-News
RKDA-Events
Arcadia Biosciences Files to Sell 11.92M Shares of Common Stock
Arcadia Biosciences files to sell 11.92M shares of common stock for holders
Arcadia Biosciences Sells 3,883,496 Shares at $1.03 Each
Arcadia Biosciences announced that it has entered into securities purchase agreements for the purchase and sale of 3,883,496 shares of its common stock , Series A-1 preferred investment options to purchase up to an aggregate of 3,883,496 shares of common stock and Series A-2 preferred investment options to purchase up to an aggregate of 3,883,496 shares of common stock at a purchase price of $1.03 per share of common stock (or pre-funded warrant in lieu thereof) and associated preferred investment options in a private placement priced at-the-market under Nasdaq rules. H.C. Wainwright & Co. is acting as the exclusive placement agent for the offering.
Arcadia Biosciences Files to Sell 1.67M Shares of Common Stock
Arcadia Biosciences files to sell 1.67M shares of common stock for holders
Rockwell Medical Sees Q4 Gross Margin Rise to 22%
Sees Q4 gross margin 22%, up from 14% in Q3. Sees Q4 cash flow from operations $2.3M, which represents the second cash flow positive quarter in 2025. As a result, cash and cash equivalents and investments available-for-sale at December 31, 2025 are expected to increase to approximately $25M. "Our preliminary financial results for the fourth quarter 2025 reflect our unrelenting drive towards making Rockwell Medical a profitable company and positioning the Company for long-term stability and success," said Mark Strobeck, CEO. "We saw a considerable increase in revenue, were cash flow positive, were Adjusted EBITDA positive, and we improved our cash position. Additionally, we continued to improve on our operational efficiencies and reduce expenses, which resulted in a gross margin of 22% in Q4, representing a notable improvement over every quarter in 2025. As we look to 2026, we are focused on three main areas: revenue growth, increased profitability, and portfolio diversification."
Arcadia Biosciences Issues Preferred Investment Options, Raises Approximately $2.1M
Arcadia Biosciences has entered into definitive agreements for the immediate exercise of certain outstanding preferred investment options to purchase up to an aggregate of 808,595 shares originally issued in December 2020, January 2021, August 2022 and March 2023, having an exercise price of $9.00 per share, at a reduced exercise price of $2.575 per share. The shares of common stock issuable upon exercise of the preferred investment options are registered pursuant to effective registration statements on Form S-1 and Form S-3. The gross proceeds to the company from the exercise of the preferred investment options are expected to be approximately $2.1M, prior to deducting placement agent fees and offering expenses. H.C. Wainwright & Co. is acting as the exclusive placement agent for the offering. In consideration for the immediate exercise of the preferred investment options for cash, Arcadia will issue new unregistered preferred investment options to purchase up to 1,617,190 shares of common stock. The new preferred investment options will have an exercise price of $2.325 per share, will be exercisable immediately and will expire thirty months after the effective date of the Resale Registration Statement. The offering is expected to close on or about January 12, 2026, subject to satisfaction of customary closing conditions. Arcadia intends to use the net proceeds from the offering for working capital and general corporate purposes.
Diese Seite dient nur der Recherche und ist keine Anlageberatung. Modelle können falsch liegen. Vergangene Wertentwicklung ist kein Indikator für die Zukunft.